manag meet sf
see recent ayvakit approv tip iceberg rel valu
perspect potenti approv larger indic ahead comfort
tavaliss expect aim least deal earli inflammatori target
possibl similar sny/dnli deal three key data readout
success could offer meaning upsid updat
model preliminari report
buy attend analyst event jeff alber ceo
discuss ayvakit launch regulatori file delay asm ism late-
break abstract aaaai philadelphia pa pralsetinib data
comment ayvakit expect vs ours/con
approv pdgfr exon gist note
tip iceberg rel valu perspect potenti approv larger
indic gist asm ism ahead start gist voyag
data gist guid next step asm delay top-line
pathfind data nda file avapritinib vs prior see
wait addit data iwg-evalu pt start dose request
fda opportun strengthen label robust dataset vs
iwg-evalu data ret inhibitor pralsetinib roll
nda complet see import distinct vs competitor
yet reach vs higher cr rate daili dose vs daili
buy met raul rodriguez ceo dean schorno
provid guidanc seem comfort our/con tavaliss us
sale estimate increas cumul patient refil rate month
vs steadi growth sinc launch eu approv
tavaliss chronic itp trigger mileston partner grifol
expect eu launch royalti start mid-teen high
preliminari tavaliss sale q/q vs prior/con
detail launch metric chart revenu vs prior/con
indic waiha note acceler enrol
enrol last two month complet track data
one top prioriti secur co-development/-promot
partner and/or program two high-interest immunolog target
pharma per refer sanofi/denali deal denali
two inhibitor garner up-front potenti mileston
 royalti announc indic either co-developed/-
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
commerci neurolog indic sole sanofi system inflammatori
pleas see import disclosur inform page report
summari chang
pleas see import disclosur inform page report
prime buy met william ringo ceo chairman
four key data catalyst includ data combin
keytruda ovarian cancer hope see orr data
cabiralizumab pancreat cancer collabor futil analysi
bemarituzumab fight indic good probabl partnership
opportun updat data search new ceo
expect posit fill priorit leadership skill
diseas state experi experi street commun knowledg
build momentum compani find partner bemarituzumab continu
discuss interest parti confid secur partner follow
futil analysi data expect ideal would maintain co-promot right
bemarituzumab us done cabiralizumab
hold updat estim follow
announc preliminari revenu growth vs prior/con estimate
announc preliminari revenu growth vs
metabol franchis sale vs prior/con estimate number
soliri gmg nmosd patient us vs
ultomiri pnh convers rate vs
goal expect expand gmg nmosd treat
patient us pre-announce revenu growth surpass
high end guidanc vs y/i growth vs prior/con
up revenu estimate
vs con increas ep
pipelin updat includ initi ultomiri al initi
al amyloidosi enrol wilson
diseas complet top-lin data begin data ultomiri
sc potenti launch pnh/ahu data danicopan
 initi danicopan pnh data
data poc studi initi indic
select work on-going initi iv waiha later
initi sc gmg launch high concentr ultomiri
infus time vs hour current new renal basket studi
time share
jefferi compani report
pleas see import disclosur inform page report
bottl ship specialti bottl ship patient total bottl bottl remain distribut channel total bottl launch metricstavaliss bottlestavaliss sale equiti research
compani report jefferi
pleas see import disclosur inform page report
fostamatinib itp growth growth tavaliss itp ex-u growth warm aiha us growth growth q/qroyalti tavaliss warm aiha ex-u growth growth good sold gross margin growth total growth total subleasetot expens loss oper growth incom expens loss tax tax incom loss lp basic lp growth y/i dilut basic equival incom statement thousand except per share equiti research
jefferi compani report
pleas see import disclosur inform page report
salessoliris/ultomiri growth growth asfotas growth growth sebelipas growth growth growth q/q growth total growth good sold gross growth total growth total growth margin incom net earn loss provis tax non-gaap tax rate incom loss non-gaap growth margin basic dilut non-gaap growth growth dilut share dilut share cash equival alexion pharmaceut inc pro-forma incom statement thousand except per share rigel inc
tavaliss market itp second
indic warm aiha assum probabl
cash plu mileston relat eu
approv tavaliss cash loan credit facil
suffici break even anticip
estim
pt base tavaliss itp
sh tavaliss warm aiha earli
tavaliss approv second indic warm
autoimmun hemolyt anemia waiha see fair
valu
tavaliss fail gain regulatori approv
second indic aiha earli program fail
tavaliss sale itp lower
estim see fair valu
view peak annual us sale estim
tavaliss itp modest given combin us sale
tpo mimet promacta nplate
combin ww sale addit
given approv therapi waiha similar market
size itp approv view peak us sale
estim tavaliss waiha would like
top-line data tavaliss waiha
enrol complet
secur co-development/-promot partner
and/or program
pleas see import disclosur inform page report
estim revenue/ep compound-annual-growth-rate
pt base sum-of-the-part npv
analysi soliris/ultomiri indic includ
pnh ahu gmg
nmo strensiq kanuma
lald wilson diseas
danicopan pnh danicopan
potenti acquisit pharma
pipelin product
price impact biosimilar and/or new
competitor product lower expect
current
estim see fair value-per-share
impact soliris/ultomiri
compet trial competit product
plateau soliris/ultomiri sale compet
biosimilar and/or complement inhibitor
pnh/ahus/gmg enter market
biosimilar and/or new competitor product
success launch activ price
pressur impact market loss see
fair value-per-share
soliris/ultomiri franchis account
total revenu conveni dose
follow-on product ultomiri make effort
fend potenti futur competit pnh ahu gmg
howev think may suffici fulli
protect franchis potenti market entri
biosimilar well new chemic entiti
even soliris/ultomiri maintain major market share
activ price pressur competit affect
revenu growth view
pk-base data ultomiri sc
potenti launch pnh/ahu
data danicopan initi
danicopan pnh start
pnh
data
data poc studi
initi
time vs hour current
enrol wilson diseas
complet top-lin data begin
pleas see import disclosur inform page report
